---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-001760"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-01-04T23:59:59+00:00"
generated_at: "2026-06-27T21:01:39.358551+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics appoints Esther Rajavelu as CFO and Treasurer

## Summary
- Esther Rajavelu appointed CFO and Treasurer effective Jan 3, 2022; Peter Thomson ceases as principal financial officer.
- Rajavelu receives $435,000 annual base salary, $150,000 signing bonus, and 200,000 stock option at $17.82/share.
- Option vests 25% on first anniversary, then 6.25% quarterly over 12 quarters.
- Rajavelu has ~20 years life sciences experience including UBS, Oppenheimer, Deutsche Bank, and EY Capital.
- Press release highlights two disease-modifying programs (losmapimod for FSHD, FTX-6058 for sickle cell).

## SEC filing metadata
- accession: 0001193125-22-001760
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/d237013d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-001760
- JSON: https://secwatch.observer/filing/0001193125-22-001760.json
- Plain text: https://secwatch.observer/filing/0001193125-22-001760.txt

## Key facts
- Executive change
  Peter Thomson changed role as Principal Financial Officer at Fulcrum Therapeutics, Inc..
  - Action: ceased
  - Role: Principal Financial Officer
  source text: As a result of Ms. Rajavelu’s appointment, Peter Thomson, the Company’s Vice President, Finance and Accounting, will cease to serve as principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm
- Executive change
  Esther Rajavelu was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Treasurer
  source text: On January 3, 2022, the Board of Directors (the “Board”) of Fulcrum Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Treasurer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.